| Half-life | 45 days |
| Clearance Route | mixed |
| Active Metabolites | Desethylhydroxychloroquine, desethylchloroquine |
| Notes | Very long terminal half-life (up to 45 days). Risk of retinal toxicity with long-term use; avoid overdose. |
Severity: Moderate
Adverse Effects:
Retinopathy, QT prolongation, hypoglycemia, GI upset, rash, pruritus, dizziness.
Contraindications:
Pre-existing retinopathy, G6PD deficiency relative contraindication, QT prolongation syndromes.
Precautions:
Baseline and periodic eye exam; caution with other QT-prolonging drugs; adjust dose in renal impairment.